| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Oral Genome, a leading innovator in salivary testing, today announced a strategic partnership with Henry Schein, the world's largest provider of health care solutions to office-based dental and medical practitioners. This collaboration aims to bring Oral Genome's cutting-edge point-of-care saliva testing to dental and medical practices nationwide, advancing the integration of oral and systemic health care.
The partnership will roll out through Henry Schein's distribution channels, targeting dental practices, community health clinics, and medical offices seeking new preventive care techniques. This initiative underscores both companies' dedication to advancing health care through technology and collaboration.
Posted In: HSIC
